Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRLHR | P49683 | 15/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22424568 | 0.92 | PRLHR (0.51) | PRLHRHDAC6GRM5MAPK1HTR1A | |
| SCHEMBL22424695 | 0.90 | PRLHR (0.53) | PRLHRHDAC6GRM5HTR1A | |
| SCHEMBL22424283 | 0.88 | PRLHR (0.50) | PRLHRHDAC6GRM5HTR1A | |
| SCHEMBL22424573 | 0.88 | PRLHR (0.51) | PRLHRHDAC6GRM5HTR1A | |
| SCHEMBL22424690 | 0.88 | PRLHR (0.49) | PRLHRHDAC6GRM5HTR1A | |
| SCHEMBL22424555 | 0.88 | PRLHR (0.51) | PRLHRHDAC6GRM5HTR1A | |
| SCHEMBL22424014 | 0.88 | PRLHR (0.51) | PRLHRHDAC6GRM5 | |
| SCHEMBL22424571 | 0.88 | PRLHR (0.51) | PRLHRHDAC6GRM5HTR1A | |
| SCHEMBL22410896 | 0.87 | PRLHR (0.49) | PRLHRHDAC6GRM5HTR1A | |
| SCHEMBL22424687 | 0.87 | PRLHR (0.49) | PRLHRHDAC6GRM5HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |